J&J wins full ap­proval for blad­der can­cer drug

The FDA on Fri­day con­vert­ed its ac­cel­er­at­ed ap­proval of John­son & John­son’s blad­der can­cer drug Balver­sa to a full ap­proval.

Balver­sa, al­so known as erdafi­tinib, be­came the first FDA-ap­proved FGFR ki­nase in­hibitor in 2019 af­ter a small­er study showed that al­most one-third of blad­der can­cer pa­tients saw their tu­mors shrink. The full ap­proval comes six weeks ahead of sched­ule and fea­tures sev­er­al changes to the la­bel.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER